661 related articles for article (PubMed ID: 24269664)
41. Clozapine blockade of MK-801-induced learning/memory impairment in the mEPM: Role of 5-HT
López Hill X; Richeri A; Scorza MC
Physiol Behav; 2017 Oct; 179():346-352. PubMed ID: 28705535
[TBL] [Abstract][Full Text] [Related]
42. Glycinamide prevents MK-801-induced hyperactivity and deficits in object recognition memory in an animal model of positive and cognitive symptoms of schizophrenia.
Basurto E; Flores OG; Hoffman KL
Schizophr Res; 2015 Aug; 166(1-3):349-50. PubMed ID: 25823398
[No Abstract] [Full Text] [Related]
43. Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia.
Gururajan A; Taylor DA; Malone DT
Behav Brain Res; 2011 Sep; 222(2):299-308. PubMed ID: 21458498
[TBL] [Abstract][Full Text] [Related]
44. Atypical but not typical antipsychotic drugs ameliorate phencyclidine-induced emotional memory impairments in mice.
Adem A; Madjid N; Stiedl O; Bonito-Oliva A; Konradsson-Geuken Å; Holst S; Fisone G; Ögren SO
Eur Neuropsychopharmacol; 2019 May; 29(5):616-628. PubMed ID: 30910381
[TBL] [Abstract][Full Text] [Related]
45. Two learning tasks provide evidence for disrupted behavioural flexibility in an animal model of schizophrenia-like behaviour induced by acute MK-801: a dose-response study.
Lobellova V; Entlerova M; Svojanovska B; Hatalova H; Prokopova I; Petrasek T; Vales K; Kubik S; Fajnerova I; Stuchlik A
Behav Brain Res; 2013 Jun; 246():55-62. PubMed ID: 23499708
[TBL] [Abstract][Full Text] [Related]
46. The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone.
Horisawa T; Nishikawa H; Toma S; Ikeda A; Horiguchi M; Ono M; Ishiyama T; Taiji M
Behav Brain Res; 2013 May; 244():66-9. PubMed ID: 23376699
[TBL] [Abstract][Full Text] [Related]
47. A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia.
Gil-Ad I; Portnoy M; Tarasenko I; Bidder M; Kramer M; Taler M; Weizman A
Eur Neuropsychopharmacol; 2014 Mar; 24(3):425-36. PubMed ID: 24389121
[TBL] [Abstract][Full Text] [Related]
48. Predicting drug efficacy for cognitive deficits in schizophrenia.
Hagan JJ; Jones DN
Schizophr Bull; 2005 Oct; 31(4):830-53. PubMed ID: 16177277
[TBL] [Abstract][Full Text] [Related]
49. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat.
Grayson B; Idris NF; Neill JC
Behav Brain Res; 2007 Nov; 184(1):31-8. PubMed ID: 17675172
[TBL] [Abstract][Full Text] [Related]
50. Effects of the Glycine Transporter-1 Inhibitor Iclepertin (BI 425809) on Sensory Processing, Neural Network Function, and Cognition in Animal Models Related to Schizophrenia.
Rosenbrock H; Dorner-Ciossek C; Giovannini R; Schmid B; Schuelert N
J Pharmacol Exp Ther; 2022 Aug; 382(2):223-232. PubMed ID: 35661632
[No Abstract] [Full Text] [Related]
51. The effects of clozapine on cognitive functioning in schizophrenia.
McGurk SR
J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
[TBL] [Abstract][Full Text] [Related]
52. Nicotinic-antipsychotic drug interactions and cognitive function.
Levin ED; Rezvani AH
EXS; 2006; 98():185-205. PubMed ID: 17019889
[TBL] [Abstract][Full Text] [Related]
53. Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-D-aspartate (NMDA) glutamatergic receptor blockade.
Levin ED; Petro A; Caldwell DP
Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):581-6. PubMed ID: 15866361
[TBL] [Abstract][Full Text] [Related]
54. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial.
Chung YC; Lee CR; Park TW; Yang KH; Kim KW
World J Biol Psychiatry; 2009; 10(2):156-62. PubMed ID: 19514097
[TBL] [Abstract][Full Text] [Related]
55. RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia.
Rajagopal L; Kwon S; Huang M; Michael E; Bhat L; Cantillon M; Meltzer HY
Behav Brain Res; 2017 Aug; 332():180-199. PubMed ID: 28373127
[TBL] [Abstract][Full Text] [Related]
56. Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior.
Choy KH; Shackleford DM; Malone DT; Mistry SN; Patil RT; Scammells PJ; Langmead CJ; Pantelis C; Sexton PM; Lane JR; Christopoulos A
J Pharmacol Exp Ther; 2016 Nov; 359(2):354-365. PubMed ID: 27630144
[TBL] [Abstract][Full Text] [Related]
57. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors.
Corbett R; Camacho F; Woods AT; Kerman LL; Fishkin RJ; Brooks K; Dunn RW
Psychopharmacology (Berl); 1995 Jul; 120(1):67-74. PubMed ID: 7480537
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia.
Chaki S; Shimazaki T; Karasawa J; Aoki T; Kaku A; Iijima M; Kambe D; Yamamoto S; Kawakita Y; Shibata T; Abe K; Okubo T; Sekiguchi Y; Okuyama S
Psychopharmacology (Berl); 2015 Aug; 232(15):2849-61. PubMed ID: 25869273
[TBL] [Abstract][Full Text] [Related]
59. Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in
Nakashima M; Imada H; Shiraishi E; Ito Y; Suzuki N; Miyamoto M; Taniguchi T; Iwashita H
J Pharmacol Exp Ther; 2018 Apr; 365(1):179-188. PubMed ID: 29440309
[TBL] [Abstract][Full Text] [Related]
60. Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance.
Pedersen CS; Goetghebeur P; Dias R
J Neurosci Methods; 2009 Dec; 185(1):66-9. PubMed ID: 19761795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
